Technology | May 15, 2013

FDA Clears RayStation 3.5 Treatment Planning System

In March, RaySearch Laboratories AB announced that version 3.5 of RaySearch's RayStation treatment planning system had been released for clinical use. RaySearch has now received 510(k) clearance from the FDA for RayStation 3.5 meaning that the new features can be marketed in the U.S. 

The most important new features are state of-the-art tools for treatment planning of radiation therapy with electrons and protons, complementing RayStation’s extensive tools for planning and optimization of radiation therapy with photons. Proton Beam Design is a brand new module in RayStation that contains tools for treatment planning of double scattered and uniformly scanned protons, such as a clinically approved Pencil Beam dose engine and automatic generation of treat-and-protect beams. This is the first clinical release of proton planning functionality in RayStation, to be followed by many others, such as Pencil Beam Scanning techniques and Monte Carlo dose calculations. Electron Beam Design is another entirely new module that includes a Monte Carlo dose engine for electron radiation therapy and tools for manual editing of beams similar to how it is done in the 3D-CRT module.

In addition the new version contains a wide range of other new features and improvements.

“We are of course happy that we now have a complete offering for our US customers, with support for all treatment modalities including protons and electrons, and support all IMRT and VMAT delivery modes with all relevant treatment machines. This new version also includes some highly useful tools to improve the clinical workflow and further expands our market-leading toolbox for adaptive 4D treatments, which I believe further cements RayStation’s position as the most advanced treatment planning system on the US market”, said Johan Löf, CEO of RaySearch.

RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4-D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.

For more information: www.raysearchlabs.com

Related Content

MedStar Georgetown Proton Center Selects RayStation for Treatment Planning
News | Treatment Planning | August 17, 2017
August 17, 2017 — The proton center at MedStar Georgetown University Hospital will utilize RayStation for planning on
DOSIsoft Releases ISOgray Proton Therapy Treatment Planning System
Technology | Treatment Planning | August 15, 2017
DOSIsoft SA announced the official release, with CE marking, of ISOgray Treatment Planning System (TPS) release 4.3 for...
Accuray Receives 510(k) Clearance for iDMS Data Management System
Technology | Oncology Information Management Systems (OIMS) | July 31, 2017
July 31, 2017 — Accuray Inc. announced it has received 510(k) clearance from the U.S.
more healthcare providers and patients are choosing options such as Gamma Knife stereotactic radiosurgery
News | Radiation Therapy | July 31, 2017
Each year, up to 650,000 people who were previously diagnosed with various forms of cancer will develop brain...
Eight Proton Therapy Centers Worldwide Adopt RayStation for Treatment Planning
News | Treatment Planning | July 21, 2017
RaySearch Laboratories reported that eight additional proton therapy centers worldwide have recently chosen RayStation...
Catharina Hospital

Catharina Hospital

Sponsored Content | Case Study | Treatment Planning | July 05, 2017
Recently, the oncology department needed to update its radiation therapy treatment planning system. The department...
Elekta’s MR-linac integrates an advanced linear accelerator and a 1.5T magnetic resonance imaging (MRI) system

Elekta’s MR-linac integrates an advanced linear accelerator and a 1.5T magnetic resonance imaging (MRI) system. Combined, these systems will allow for simultaneous radiation therapy delivery and high-field MR tumor monitoring.

Feature | Radiation Oncology | July 05, 2017 | By Jeff Zagoudis
Image-guided radiation therapy offers great potential to improve the efficiency of treating cancer patients by more...

Photo courtesy of RaySearch

Feature | Treatment Planning | July 05, 2017 | By Jeff Zagoudis
While radiation oncologists have a number of proven techniques at their disposal for treating patients, the reality is...
IBA and Philips Step Up Commercial Collaboration in Brazilian Proton Therapy Market
News | Radiation Therapy | July 03, 2017
IBA and Philips announced in mid-June they are stepping up their combined effort for proton therapy in Brazil.
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
Overlay Init